Literature DB >> 10910226

Urinary tract cancer screening through analysis of urinary red blood cell volume distribution.

M Wakui1, T Shiigai.   

Abstract

BACKGROUND: Hematuria is differentiated between glomerular and urinary tract origins on the basis of urinary red cell morphology. We used this distinction in a program of mass screening for urinary tract cancer to achieve cost-effective and safe hematuria screening.
METHODS: Of a total of 21372 adults (mean age 52.3 years; range 20-79 years) participating in a health screening, 912 (4.3%) had a positive dipstick for hematuria and were enrolled in the present study. Urinary red cell volume distribution curves (RDC), the simplest method of assessing urinary red cell morphology, were calculated and subjects were divided into two groups based on their RDC patterns. Group I subjects had a normocytic or mixed pattern and they were immediately investigated for urinary tract malignancy because of the associated risk for urological disease. Group II subjects had a microcytic pattern and, therefore, were judged to be at a low risk of urologic malignancy and were followed up 3 years later without urologic investigations.
RESULTS: Among the 38 subjects in group I (4% of all dipstick-positive subjects), one case of bladder cancer was detected. In the remaining 37 patients, 15 cases of benign diseases were discovered. Group II was composed of 869 subjects (96%). The inquiry into their health status conducted 3 years later revealed that 831 (95.6%) were healthy and, of these, 13 had experienced gross hematuria during the period but urological malignancies were ruled out by their urologists, two (0.2%) had died of diseases other than urological cancer and 36 (4.1%) were lost to follow-up. With our method, total costs have been reduced by 93.8% against a conventional setting of a full evaluation for all cases of hematuria.
CONCLUSIONS: Microcytic hematuria, accounting for 96% of asymptomatic microhematuria cases in the present study, was not associated with a risk for urinary tract malignancy. Compared with conventional hematuria screening with a complete work-up of all cases of hematuria, investigating only subjects with mixed or normocytic RDC patterns was safe and cost effective.

Entities:  

Mesh:

Year:  2000        PMID: 10910226     DOI: 10.1046/j.1442-2042.2000.00184.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  7 in total

Review 1.  Molecular screening for bladder cancer: progress and potential.

Authors:  Anirban P Mitra; Richard J Cote
Journal:  Nat Rev Urol       Date:  2010-01       Impact factor: 14.432

2.  In vitro regulation of cell growth and angiogenesis by inositol hexaphosphate in bladder cancer.

Authors:  Stanley J Kandzari; Dale Riggs; Barbara Jackson; Adam Luchey; Claire Oliver; Stanley Zaslau
Journal:  Curr Urol       Date:  2013-02-08

3.  Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.

Authors:  R S van der Post; L A Kiemeney; M J L Ligtenberg; J A Witjes; C A Hulsbergen-van de Kaa; D Bodmer; L Schaap; C M Kets; J H J M van Krieken; N Hoogerbrugge
Journal:  J Med Genet       Date:  2010-07       Impact factor: 6.318

4.  Comparison of dynamic contrast-enhanced and diffusion weighted magnetic resonance image in staging and grading of carcinoma bladder with histopathological correlation.

Authors:  Neetika Gupta; Binit Sureka; Mittal Mahesh Kumar; Amita Malik; Thukral Brij Bhushan; N K Mohanty
Journal:  Urol Ann       Date:  2015 Apr-Jun

Review 5.  Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions.

Authors:  Chulso Moon; Maxie Gordon; David Moon; Thomas Reynolds
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

6.  Review: Application of Nanoparticles in Urothelial Cancer of the Urinary Bladder.

Authors:  Chieh-Hsiao Chen; Tzu-Min Chan; Yi-Jhen Wu; Jia-Jin Chen
Journal:  J Med Biol Eng       Date:  2015-08-11       Impact factor: 1.553

7.  Incidental Diagnosis of Bladder Cancer in a 17-year-old Patient.

Authors:  Fernando Nestor Facio; Maria Fernanda W Facio; Luis Cesar F Spessoto; Marcio Gatti; Pedro F Ferraz Arruda; Jose G Ferraz Arruda; Luis Francisco B Gabriotti; Pedro Paulo Silva L Polotto
Journal:  Urol Case Rep       Date:  2015-05-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.